Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354543 | 1.00 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL11487828 | 0.86 | SMN1; SMN2 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL19319049 | 0.85 | TBXAS1 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL2628037 | 0.85 | SMN1; SMN2 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL11088662 | 0.85 | SMN1; SMN2 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL17308611 | 0.85 | SMN1; SMN2 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL306372 | 0.84 | F7 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL3644679 | 0.83 | SMN1; SMN2 (0.52) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL16444687 | 0.83 | SMN1; SMN2 (0.52) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL3616276 | 0.83 | SMN1; SMN2 (0.52) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579320-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| CN-104230911-A | 2, 6-diamino- pyrimidin- 5-yl-carboxamides compounds as SYK or JAK kinases inhibitors | PORTOLA PHARM INC | 2014-12-24 | — | — | CN | disclosed |
| US-20130165431-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8349860-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8318755-B2 | Inhibitors of SYK and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2323993-A2 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-102066339-A | 2, 6-diamino-pyrimidin-5-yl-carboxamides as SYK or JAK protein kinase inhibitors | PORTOLA PHARM INC | 2011-05-18 | — | — | CN | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009136995-A2 | INHIBITORS OF SYK PROTEIN KINASE | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | F7 325/4885F3 56/4885SARM1 4709/4885 |
| US-20130165431-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | F7 325/4885F3 56/4885SARM1 4709/4885 |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | F7 4843/4885F3 3503/4885SARM1 628/4885 |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | F7 325/4885F3 56/4885SARM1 4709/4885 |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | F7 325/4885F3 56/4885SARM1 4709/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | F7 325/4885F3 56/4885SARM1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.